Shanghai Pharmaceuticals Subsidiary's Clevidipine Injectable Emulsion Approved for Production

财中社··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Shanghai Pharmaceuticals announced on October 9 that its subsidiary SPH No.1 Biochemical & Pharmaceutical has received the Drug Registration Certificate for Clevidipine Injectable Emulsion from the National Medical Products Administration. The drug has been approved for production and is mainly used to treat hypertension in patients for whom oral medication is unsuitable or expected to be ineffective. As of the announcement date, the company has invested approximately 52.2 million yuan in research and development for this drug. According to the IQVIA database, in 2025, the procurement amount of injectable calcium channel blockers with the same mechanism as Clevidipine Injectable Emulsion in mainland China hospitals was 911 million yuan. In the first half of 2026, Shanghai Pharmaceuticals achieved revenue of 147.47 billion yuan and net profit attributable to the parent company of 3.504 billion yuan.

Impact on assets 1

Others▲

Off-coverage companies 1

Shanghai SPH First Biochemical Pharmaceutical Co Ltdi
Private▲ PositiveRegulationrelevance

SPH No.1 Biochemical & Pharmaceutical received the Drug Registration Certificate for Clevidipine Injectable Emulsion, approving production.